<DOC>
	<DOCNO>NCT01561768</DOCNO>
	<brief_summary>The purpose study determine immune response three dose level Novavax Quadrivalent vaccine healthy young adult ( 18-64 ) . The study break 5 treatment group . Each group enroll 100 subject , total 500 subject . Group 1-3 receive one three dose level Novavax Quadrivalent vaccine , Group 4 receive dose Novavax Trivalent vaccine , Group 5 receive commercially available trivalent influenza vaccine ( TIV ) . The study also evaluate safety tolerability Novavax Quadrivalent vaccine .</brief_summary>
	<brief_title>A Study Evaluate Immune Response Safety Seasonal Virus-Like Particle Influenza Vaccine Healthy Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy adult male female , 1864 year age 2 . Willing able give inform consent prior study enrollment 3 . Able comply study requirement 4 . Women postmenopausal ( ≥ 50 year age least one year post last menses ) surgically sterile must negative urine pregnancy test vaccination ; advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history abstinence heterosexual activity , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , doublebarrier contraceptive ( condom diaphragm , spermicide ) , intrauterine device ( IUD ) 1 . Participation research involve investigational product ( drug/biologic/device ) within 45 day plan date first vaccination 2 . History serious reaction prior influenza vaccination , know allergy constituent license TIV ( e.g. , egg protein ) polysorbate80 3 . History GuillainBarré Syndrome ( GBS ) within 6 week follow previous influenza vaccine 4 . Received vaccine 4 week precede study vaccination influenza vaccine within six month precede study vaccination 5 . Any know suspect immunosuppressive illness , congenital acquire , base medical history and/or physical examination 6 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10 mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 7 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study 8 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration ) 9 . Presence chronic pulmonary ( include asthma ) , cardiovascular ( except hypertension ) , renal , hepatic , neurologic , hematologic metabolic ( include diabetes mellitus ) disorder , would include potential subject `` highrisk '' category influenza and/or complication 10 . Known disturbance coagulation 11 . Women breastfeed plan become pregnant study 12 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse 13 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic psychiatric condition deem likely impair quality safety reporting )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>